stockportfolio.pro
Stocks / DOCS vs KNSA
DOCS vs KNSA
Doximity, Inc. and Kiniksa Pharmaceuticals International, plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Doximity, Inc. (DOCS) | Kiniksa Pharmaceuticals International, plc (KNSA) | |
|---|---|---|
| Market cap | $3.7B | $3.9B |
| Revenue (latest FY) | $644.86M | $677.56M |
| Net income (latest FY) | $196.05M | $59.01M |
| Revenue growth (5y CAGR) | 25.5% | — |
| Net margin | 30.4% | 8.7% |
| Return on equity | 20.6% | 10.4% |
| P/E ratio | 20.6 | 55.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 3 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DOCS — free Open KNSA — freeFrequently asked questions
Which is bigger, DOCS or KNSA?
Kiniksa Pharmaceuticals International, plc is larger by market capitalization — $3.9B versus $3.7B.
Which grows faster, DOCS or KNSA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.